Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC) - Episode 13

Insights Into Ongoing Investigational Studies in Lung LCNEC

,

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro
    EP. 2: An Overview of the Molecular Characterization of Lung LCNEC
    EP. 3: The Pathological Diagnosis of Lung LCNEC
    EP. 4: Biomarker Testing Strategies for Lung LCNEC
    EP. 5: Biopsy Best Practices: Diagnosing Lung LCNEC
    EP. 6: Lung LCNEC Diagnostic Challenges
    EP. 7: A Multidisciplinary Approach to Managing Lung LCNEC
    EP. 8: Lung LCNEC Disease Histology and Prognosis
    EP. 9: The Role of DLL3 in LCNEC of the Lung
    EP. 10: Insights on the LANCE Pilot Study on Lung LCNEC
    EP. 11: Novel Targeted Therapies for LCNEC of the Lung
    EP. 12: Overview of Studies of BI 764532 for Lung LCNEC
    Now Viewing
    EP. 13: Insights Into Ongoing Investigational Studies in Lung LCNEC
    EP. 14: Potential Next-Generation Therapies for Lung LCNEC
    EP. 15: Unmet Needs in LCNEC
    • Please briefly describe and provide any thoughts for ongoing lung LCNEC trials, with both familiar and novel agents:
      • Phase II durvalumab + EP, 1L
      • Phase 2 LCNEC-ALPINE atezolizumab + EP, 1L
      • Phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific ab, 2L+
      • Phase 1 LB2102 DLL2-directed CAR T, 2L+
    x